The Medicare Rights Center reports that President Trump’s executive order on prescription drug pricing supports key drug ...

Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...